ARCHIVES

Phase III Trial of ThermoDox Fails to Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 2 | February 22, 2013

Download PDF Visit The Full Archive

Related Articles

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

December 31, 2010

Continuing Resolution Expires March 27; NIH, NCI Hope For Budget Compromise

March 15, 2013

Von Eschenbach says oncology is undergoing a “revolutionary evolution.”

May 20, 2005

Cancer Policy Board urges distinct care for cancer survivors.

November 11, 2005

In Brief: Baylor Recruits Scardino, Osborne, 13 Others; Likely To Gain Its Second NCI SPORE Grants

April 30, 1999

Peers Puzzled By Herberman’s Stance On Cell Phones While Believers Rally.

August 1, 2008